Cargando…

A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study

OBJECTIVE: Pancreatic body tail carcinoma (PBTC) is a relatively few pancreatic cancer in clinical practice, and its specific clinicopathological features and prognosis have not been fully described. In this study, we aimed to create a nomogram to predict the overall survival (OS) of patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Huaqing, Chen, Zhou, Dong, Shi, He, Ru, Du, Yan, Qin, Zishun, Zhou, Wence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164315/
https://www.ncbi.nlm.nih.gov/pubmed/35658912
http://dx.doi.org/10.1186/s12876-022-02362-2
_version_ 1784720107449090048
author Shi, Huaqing
Chen, Zhou
Dong, Shi
He, Ru
Du, Yan
Qin, Zishun
Zhou, Wence
author_facet Shi, Huaqing
Chen, Zhou
Dong, Shi
He, Ru
Du, Yan
Qin, Zishun
Zhou, Wence
author_sort Shi, Huaqing
collection PubMed
description OBJECTIVE: Pancreatic body tail carcinoma (PBTC) is a relatively few pancreatic cancer in clinical practice, and its specific clinicopathological features and prognosis have not been fully described. In this study, we aimed to create a nomogram to predict the overall survival (OS) of patients with advanced PBTC. METHODS: We extracted clinical and related prognostic data of advanced PBTC patients from 2000 to 2018 from the Surveillance, Epidemiology, and End Results database. Independent prognostic factors were selected using univariate and multivariate Cox analyses, and a nomogram was constructed using R software. The C-index, area under the curve (AUC) of receiver operating characteristic curves, calibration curves, and decision curve analysis (DCA) were used to assess the clinical utility of the nomogram. Finally, OS was assessed using the Kaplan–Meier method. RESULTS: A total of 1256 patients with advanced PBTC were eventually included in this study. Age, grade, N stage, M stage, surgery, and chemotherapy were identified as independent risk factors using univariate and multivariate Cox regression analyses (p < 0.05). In the training cohort, the calibration index of the nomogram was 0.709, while the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.777, 0.562, 0.621, 0.5, 0.576, 0.632, and 0.323, respectively. Meanwhile, in the validation cohort, the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.772, 0.551, 0.629, 0.534, 0.577, 0.606, and 0.639, respectively. Good agreement of the model in the training and validation cohorts was demonstrated in the calibration and DCA curves. Univariate survival analysis showed a statistically significant effect of age, grade, M stage, and surgery on prognosis (p < 0.05). CONCLUSION: Age, grade, M stage, and surgery were independently associated with OS, and the established nomogram was a visual tool to effectively predict OS in advanced PBTC patients.
format Online
Article
Text
id pubmed-9164315
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91643152022-06-05 A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study Shi, Huaqing Chen, Zhou Dong, Shi He, Ru Du, Yan Qin, Zishun Zhou, Wence BMC Gastroenterol Research OBJECTIVE: Pancreatic body tail carcinoma (PBTC) is a relatively few pancreatic cancer in clinical practice, and its specific clinicopathological features and prognosis have not been fully described. In this study, we aimed to create a nomogram to predict the overall survival (OS) of patients with advanced PBTC. METHODS: We extracted clinical and related prognostic data of advanced PBTC patients from 2000 to 2018 from the Surveillance, Epidemiology, and End Results database. Independent prognostic factors were selected using univariate and multivariate Cox analyses, and a nomogram was constructed using R software. The C-index, area under the curve (AUC) of receiver operating characteristic curves, calibration curves, and decision curve analysis (DCA) were used to assess the clinical utility of the nomogram. Finally, OS was assessed using the Kaplan–Meier method. RESULTS: A total of 1256 patients with advanced PBTC were eventually included in this study. Age, grade, N stage, M stage, surgery, and chemotherapy were identified as independent risk factors using univariate and multivariate Cox regression analyses (p < 0.05). In the training cohort, the calibration index of the nomogram was 0.709, while the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.777, 0.562, 0.621, 0.5, 0.576, 0.632, and 0.323, respectively. Meanwhile, in the validation cohort, the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.772, 0.551, 0.629, 0.534, 0.577, 0.606, and 0.639, respectively. Good agreement of the model in the training and validation cohorts was demonstrated in the calibration and DCA curves. Univariate survival analysis showed a statistically significant effect of age, grade, M stage, and surgery on prognosis (p < 0.05). CONCLUSION: Age, grade, M stage, and surgery were independently associated with OS, and the established nomogram was a visual tool to effectively predict OS in advanced PBTC patients. BioMed Central 2022-06-03 /pmc/articles/PMC9164315/ /pubmed/35658912 http://dx.doi.org/10.1186/s12876-022-02362-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shi, Huaqing
Chen, Zhou
Dong, Shi
He, Ru
Du, Yan
Qin, Zishun
Zhou, Wence
A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title_full A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title_fullStr A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title_full_unstemmed A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title_short A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study
title_sort nomogram for predicting survival in patients with advanced (stage iii/iv) pancreatic body tail cancer: a seer-based study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164315/
https://www.ncbi.nlm.nih.gov/pubmed/35658912
http://dx.doi.org/10.1186/s12876-022-02362-2
work_keys_str_mv AT shihuaqing anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT chenzhou anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT dongshi anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT heru anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT duyan anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT qinzishun anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT zhouwence anomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT shihuaqing nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT chenzhou nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT dongshi nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT heru nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT duyan nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT qinzishun nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy
AT zhouwence nomogramforpredictingsurvivalinpatientswithadvancedstageiiiivpancreaticbodytailcanceraseerbasedstudy